Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07247227
What this trial is testing

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Who this might be right for
NSCLC
Peking Union Medical College 150
Large-scale testing (Phase 3)Looking for participantsNCT04928846
What this trial is testing

Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
AbbVie 768
Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06182761
What this trial is testing

Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Shanghai Zhongshan Hospital 45
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Early research (Phase 1)Active Not RecruitingNCT05581004
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsNSCLCHNSCC+9 more
Genentech, Inc. 165
Testing effectiveness (Phase 2)Looking for participantsNCT07206498
What this trial is testing

Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Wayshine Biopharm, Inc. 48
Testing effectiveness (Phase 2)Study completedNCT00777309
What this trial is testing

Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 167
Testing effectiveness (Phase 2)UnknownNCT05900219
What this trial is testing

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Who this might be right for
Non-small-cell Lung Cancer
Shanghai Kechow Pharma, Inc. 75
Testing effectiveness (Phase 2)Looking for participantsNCT07489716
What this trial is testing

A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 90
Testing effectiveness (Phase 2)Study completedNCT01846416
What this trial is testing

Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc. 138
Testing effectiveness (Phase 2)Ended earlyNCT00522938
What this trial is testing

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Chroma Therapeutics 2
Early research (Phase 1)Looking for participantsNCT07390838
What this trial is testing

SH009 Injection in Patients With Advanced Solid Tumors.

Who this might be right for
Liver Cancer (Locally Advanced or Metastatic)Lung Cancer (NSCLC)Head and Neck Cancer Squamous Cell Carcinoma+4 more
Nanjing Sanhome Pharmaceutical, Co., Ltd. 150
Not applicableApproved For MarketingNCT01649284
What this trial is testing

Afatinib Expanded Access Program

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Testing effectiveness (Phase 2)UnknownNCT05519293
What this trial is testing

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
RedCloud Bio 76
Testing effectiveness (Phase 2)Ended earlyNCT02546986
What this trial is testing

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Celgene 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04035486
What this trial is testing

Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 587
Not applicableStudy completedNCT05862194
What this trial is testing

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Yuhan Corporation 534
Early research (Phase 1)Looking for participantsNCT04297605
What this trial is testing

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Who this might be right for
Non-small Cell Lung Cancer
University of Rochester 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07742956
What this trial is testing

Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Shanghai Allink Biotherapeutics Co., Ltd. 156
Next Page